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Fig. 1. HCV-kinetics during silibinin i.v. monotherapy. HCV RNA levels
measured by real-time PCR (Cobas Taqman, Roche Diagnostics, Pleasanton, CA).To the Editor:
We read with great interest the letter by Neumann et al. [1] on
the effect of Silibinin in preventing graft infection in a patient
with cirrhosis due to chronic hepatitis C (HCV). We obtained
the same result in a patient treated with intravenous (i.v.) Silibi-
nin mono-therapy (Legalon SIL, Rottapharm-Madaus).
In 1994, the 46-year-old male patient with beta-thalassemia
was ﬁrst diagnosed for HCV with mixed genotype 1a/4. Both
genotypes were also present upon starting silibinin treatment
and on the day of OLTx. In 1998, he was treated with 5 MU inter-
feron three times a week and weight based ribavirin. Treatment
was stopped due to failure to clear the virus after 24 weeks of
treatment.
In 2009, he presented with end stage liver failure (Child–Pugh
stage C, MELD 20). In the mean time, he had developed insulin
dependent diabetes mellitus which is treated with insulin aspar-
tate (Novomix 30 100 E/ml, Novo Nordisk Pharma GmbH; 16 IE-
0-0/day). He was listed for orthotopic liver transplantation (OLT)
on the 29th of October 2009. Based on our observation of the
potent antiviral effects of Silibinin [2,3] a feasibility study was
discussed in the transplant setting.
Accordingly, a patient placed ﬁrst on the waiting list for OLT
should receive i.v. Silibinin. In this patient a donor liver became
available on day 15 of Silibinin mono-therapy. The data on virus
concentrations, obtained pre and after OLT, are shown in Fig. 1.
Baseline virus load was low (28.800 IU/ml) and decreased on
intravenous Silibinin mono-therapy to 43 IU/ml on the day of
OLTx. Due to a miscommunication between our outpatient center
and the OLT-team, treatment was interrupted for 2 days after OLT
and virus concentration increased to 115 IU/ml. Nevertheless,
HCV-RNA levels decreased after resuming Silibinin-infusions to
30 IU/ml on day 6 and became unquantiﬁable (<15 IU/ml) on
day 10, and undetectable on day 22 after OLT. Silibinin was
stopped 25 days after OLT. During 5 months of follow-up, HCV-
RNA levels remained undetectable.
The surgical procedure and post-operative phase went ahead
without any complications. Immunosuppressive therapy
included prednisolone and cyclosporine A. Like in the patient of
Neumann et al. [1] bilirubin levels increased during treatment
with Silibinin to a maximum of 17.15 mg/dl (on day 3 post
OLT) but decreased continuously while the patient was still on
Silibinin. The higher increase of bilirubin in our patient could
be due to the longer administration of Silibinin combined with
the post-operative phase. Aminotransferase levels reached nearly
normal values (ASAT 39 U/l, ALAT 32 U/l) 4 days after starting Sil-Journal of Hepatology 20ibinin-infusions but increased again after OLT and reached nor-
mal levels within 4 weeks after OLT.
While the goal to prevent graft infection was reached in both
patients, the approaches were different. Neumann et al. [1]
started Silibinin application 8 h after the anhepatic phase (while
the viral load was 182 IU/ml). Our patient was pretreated with
Silibinin for 15 days with an interruption of 2 days in the post-
operative period. Previously, we have shown in a non-responders
cohort that the interruption of Silibinin treatment over the week-
end results in an increase in viral load [4]. The doses of Silibinin
were slightly different. While Neumann et al. used a ﬁxed dose
of 1400 mg/day we applied 20 mg/kg body weight/day. The low
baseline viral load may be a condition favoring the action of
Silibinin.
These encouraging observations should lead to a prospective
evaluation of i.v. Silibinin in this group of patients, having no
medical alternatives to prevent graft infection. Studies are
needed to ﬁnd the best way to apply this concept in future (tim-
ing, duration, and optimal dose).
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Reply to Beinhardt et al.:
We congratulate Beinhardt et al. for their interesting paper
about successful prevention of hepatitis C virus (HCV) reinfec-
tion by short-term administration of high-dose silibinin infu-
sions before and after OLT [1]. Preventing HCV reinfection
has an enormous impact on the long term outcome of liver
transplantation. Since interferon alpha based treatment regi-
mens are not tolerated early after OLT and also in most
instances in the pre-transplant setting, silibinin mono therapy
seems to be a promising treatment option – supported by its
reasonable safety proﬁle, as documented by its use in ama-
nita-induced acute liver failure.
Success or failure of preventing re-infection with a short term
silibinin mono therapy seems to depend mainly on the level of
hepatitis C viremia at the time of OLT. The breakdown of hepatitis
C viremia, usually seen during the anhepatic phase, works syner-
gistically with the direct antiviral effect of silibinin infusion to
support the prevention of re-infection.
As an additional mode of action, a direct inhibitory effect of
silymarin components towards the viral entry into hepatocytes
has been proposed in vitro [2].
In both cases, in ours [3] and the one reported by Beinhardt
et al. [1], HCV RNA levels were low at the time of OLT and partic-
ularly after the anhepatic phase (range of 102 IU/ml). The
approach reported here includes a silibinin treatment before
OLT, hereby signiﬁcantly lowering viremia in order to provide
beneﬁcial conditions for the successful prevention of re-infection.
This might signiﬁcantly enlarge the pool of patients beneﬁting
from post-OLT silibinin infusions. However, since the exact tim-
ing of the transplantation is usually not feasible, a standardiza-
tion of the reported procedure seems to be difﬁcult and is
probably only possible in the setting of living donor liver trans-
plantation (LDLT).
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[abstract #847].
Sandra Beinhardt1
Susanne Rasoul-Rockenschaub2
Thomas Matthias Scherzer1
Peter Ferenci1,*
1Internal Medicine III, Department of Gastroenterology
and Hepatology, Medical University of Vienna, Austria
2Division of Transplantation, Department of Surgery,
Medical University of Vienna, Austria
*Address: Internal Medicine III,
Department of Gastroenterology and Hepatology,
Medical University of Vienna,
Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Tel.: +43 1404004745; fax: +43 1404004735
E-mail address: peter.ferenci@meduniwien.ac.at (P. Ferenci)ed liver transplantation
Up to now little is known about the safety of high dose sil-
ibinin infusions in the setting of end stage chronic liver disease.
In our hands patients with advanced cirrhosis showed a
marked elevation of bilirubin (mainly indirect) in response to
silibinin infusions – an observation that was not seen in
patients with mild or moderate ﬁbrosis. The clinical signiﬁ-
cance of this bilirubin elevation remains unclear. At the same
time this ﬁnding is obviously affecting MELD-score depending
organ allocation.
Clearly the potential of silibinin infusions in the peri-trans-
plant period in HCV infected patients needs further evaluation.
Studies should address several open questions as the optimal
duration of treatment after OLT, the safety and effectiveness of
silibinin infusions before OLT, and the potentially enhancing
effect of adding ribavirin to silibinin infusions.
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